1. Sung H, Ferlay J, Siegel R, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians,2021,71(3):209-249.
2. Feng R, Zong Y, Cao S, et al. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics.Cancer communications,2019,39(1):22.
3. Galletti G, Zhang C, Gjyrezi A, et al. Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research,2020,26(14):3771-3783.
4. Lordick F, Janjigian YY. Clinical impact of tumour biology in the management of gastroesophageal cancer.2016,13(6):348-360.
5. Hudler P. Challenges of deciphering gastric cancer heterogeneity.World journal of gastroenterology,2015,21(37):10510-10527.
6. LAUREN P. The two histological main types of gastric carcinoma: diffuse and so called intestinal-type carcinoma. An attempt at a histo-clinical classification .Acta Pathol Microbiol Scand 1965,64:31-49.
7. Lee J, Park M, Kim K, et al. Advanced gastric carcinoma with signet ring cell carcinoma versus non-signet ring cell carcinoma: differentiation with multidetector CT. Journal of computer assisted tomography,2006,30(6):880-884.^
8. Xie Y, Song X, Dong W, et al. Anatomic Subsites and Prognosis of Gastric Signet Ring Cell Carcinoma: A SEER Population-Based 1 : 1 Propensity-Matched Study. BioMed research international,2022,2022:1565207.
9. Torre L, Siegel R, Ward E, et al. Global Cancer Incidence and Mortality Rates and Trends--An Update.Cancer Epidemiol Biomarkers Prev 2016,25(1):16-27.
10. Piessen G, Messager M, Leteurtre E, et al. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Annals of surgery,2009,250(6):878-887.
11. Li Y, Zhong Y, Xu Q, et al. Prognostic Significance of Signet Ring Cells in Gastric Cancer: The Higher Proportion, The Better Survival.Frontiers in oncology,2021,11:713587.
12. Wang X, Xia X, Xu E, et al. Estrogen Receptor Beta Prevents Signet Ring Cell Gastric Carcinoma Progression in Young Patients by Inhibiting Pseudopodia Formation via the mTOR-Arpc1b/EVL Signaling Pathway.Frontiers in cell developmental biology,2020,8:592919.
13. Shu Y, Zhang W, Hou Q,Zhao L, et al. Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer. Nature communications,2018,9(1):2447.
14. Huang K, Chen M, Fang W, et al. The Clinicopathological Characteristics And Genetic Alterations of Signet-ring Cell Carcinoma in Gastric Cancer.Cancers (Basel),2020,12(8):
2318.
15. Zilionis R, Engblom C, Pfirschke C, et al. Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species.Immunity,2019,50(5):1317-1334.
16. Peng J, Sun B, Chen C, et al. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma.Cell research,2019,29(9):725-738.
17. Gao S, Yan L, Wang R, Li Y,et al. Tracing the temporal-spatial transcriptome landscapes of the human fetal digestive tract using single-cell RNA-sequencing.Nature cell biology, 2018,20(6):721-734.
18. Sun Y, Wu L, Zhong Y, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma.Cell,2021,184(2):404-421.
19. Zhang P, Yang M, Zhang Y, et al. Dissecting the Single-Cell Transcriptome Network Underlying Gastric Premalignant Lesions and Early Gastric Cancer.Cell reports,2019,27(6):1934-1947.
20. Wang R, Dang M, Harada K, et al. Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nature medicine,2021,27(1): 141-151.
21. Zhou ZH, Zhang JD, Zhao HB, et al. Cell origin and premalignant lesions of gastric signetring cell carcinoma: A histopathologic study.World Chinese Journal of Digestology,2010,18(19):2001-2006.
22. Xie Y, Shi L, He X, et al. Gastrointestinal cancers in China, the USA, and Europe. Gastroenterology report,2021,9(2):91-104.
23. Pernot S, Voron T, Perkins G, et al. Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge.World journal of gastroenterology,2015,21
(40):11428-11438.
24. Mariette C, Carneiro F, Grabsch H, et al. Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma.Gastric cancer,2019,22(1):1-9.
25. Zhang C, Liu R, Zhang W, et al. Difference Between Signet Ring Cell Gastric Cancers and Non-Signet Ring Cell Gastric Cancers: A Systematic Review and Meta-Analysis.Frontiers in oncology,2021,11:618477.
26. Liu X, Cai H, Sheng W, et al. Clinicopathological Characteristics and Survival Outcomes of Primary Signet Ring Cell Carcinoma in the Stomach: Retrospective Analysis of Single Center Database.PloS one,2015,10(12):e0144420.
27. Kao Y, Fang W, Wang R, et al. Clinicopathological differences in signet ring cell adenocarcinoma between early and advanced gastric cancer.Gastric cancer,2019,22(2):255-263.
28. Bamboat Z, Tang L, Vinuela E, et al. Stage-stratified prognosis of signet ring cell histology in patients undergoing curative resection for gastric adenocarcinoma. Annals of surgical oncology,2014,21(5):1678-1685.
29. Zhang M, Hu S, Min M, et al. Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing.Gut,2021,70(3):464-475.
30. Ma L, Hernandez M, Zhao Y, et al. Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer.Cancer cell,2019,36(4):418-430.e416.
31. Xu B, Liu F, Liu Q, et al. Highly expressed Claudin18.2 as a potential therapeutic target in advanced gastric signet-ring cell carcinoma (SRCC).Journal of gastrointestinal oncology, 2020,11(6):1431-1439.
32. Meng L, Li Q, Xue Y, et al. Identification of gastric cancer-related genes by multiple high throughput analysis and data mining.Chinese journal of gastrointestinal surgery, 2007,10(2):169-172.
33. Ohnuma S, Miura K, Horii A, et al. Cancer-associated splicing variants of the CDCA1 and MSMB genes expressed in cancer cell lines and surgically resected gastric cancer tissues.Surgery,2009,145(1):57-68.
34. Zu H, Wang H, Li C, et al. Clinicopathologic characteristics and prognostic value of various histological types in advanced gastric cancer.International journal of clinical experimental pathology,2014,7(9):5692-5700.
35. Ma J, Meng Y, Zhou X, et al. The Prognostic Significance and Gene Expression Characteristics of Gastric Signet-Ring Cell Carcinoma: A Study Based on the SEER and TCGA Databases.Frontiers in surgery,2022,9:819018.
36. Altay S, Akkurt G, Yılmaz N, et al. Clinicopathological Evaluation of Gastric Signet Ring Cell Carcinoma: Our Experience. Euroasian journal of hepato-gastroenterology, 2020,10(2):76-84.
37. Muta H, Noguchi M, Kanai Y, et al. E-cadherin gene mutations in signet ring cell carcinoma of the stomach. Japanese journal of cancer research,1996,87(8):843-848.
38. Chen J, Sun D, Chu H, et al. Screening of differential microRNA expression in gastric signet ring cell carcinoma and gastric adenocarcinoma and target gene prediction.Oncology reports,2015,33(6):2963-2971.
39. Wong S, Kim K, Ting J, et al. Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing.Nature communications,2014,5:5477.
40. Jia L, Wang T, Zhao Y, et al. Single-cell profiling of infiltrating B cells and tertiary lymphoid structures in the TME of gastric adenocarcinomas.Oncoimmunology,2021,10(1):1969767.
41. Zhu Q, Guo Y, Chen S, et al. Irinotecan Induces Autophagy-Dependent Apoptosis and Positively Regulates ROS-Related JNK- and P38-MAPK Pathways in Gastric Cancer Cells. OncoTargets therapy,2020,13:2807-2817.
42. Yang M, Gu Y, Peng H, et al. NAIF1 inhibits gastric cancer cells migration and invasion via the MAPK pathways. Journal of cancer research clinical oncology,2015,141(6):1037-1047.
43. Tang W, Liu R, Yan Y, et al. Expression of estrogen receptors and androgen receptor and their clinical significance in gastric cancer.Oncotarget,2017,8(25):40765-40777.
44. Taghavi S, Jayarajan S, Davey A, et al. Prognostic significance of signet ring gastric cancer.Journal of clinical oncology 2012,30(28):3493-3498.
45. Yang X, Yang L, Mao X, et al. Pathobiological behavior and molecular mechanism of signet ring cell carcinoma and mucinous adenocarcinoma of the stomach: a comparative study.World journal of gastroenterology,2004,10(5):750-754.
46. Jin X, Wu W, Zhao J, et al. Clinical Features and Risk Factors for Lymph Node Metastasis in Early Signet Ring Cell Gastric Cancer.Frontiers in oncology,2021,11:630675.
47. Tong J, Zhang Q, Wang Z, et al. ER-α36, a novel variant of ER-α, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCδ/ERK pathway.PloS one,2010,5(11):e15408.
48. Sun Q, Liang Y, Zhang T, et al. ER-α36 mediates estrogen-stimulated MAPK/ERK activation and regulates migration, invasion, proliferation in cervical cancer cells.Biochemical,2017,487(3):625-632.
49. Caiazza F, Galluzzo P, Lorenzetti S, et al. 17Beta-estradiol induces ERbeta up-regulation via p38/MAPK activation in colon cancer cells.Biochemical,2007,359(1):102-107.
50. Powell E, Wang Y, Shapiro D, et al. Differential requirements of Hsp90 and DNA for the formation of estrogen receptor homodimers and heterodimers. The Journal of biological chemistry,2010,285(21):16125-16134.
51. Fliss A, Benzeno S, Rao J, et al. Control of estrogen receptor ligand binding by Hsp90.The Journal of steroid biochemistry,2000,72(5):223-230.
52. Dhamad A, Zhou Z, Zhou J, et al. Systematic Proteomic Identification of the Heat Shock Proteins (Hsp) that Interact with Estrogen Receptor Alpha (ERα) and Biochemical Characterization of the ERα-Hsp70 Interaction. PloS one,2016,11(8):e0160312.
53. Parker T, Gupta K, Palma A, et al. Cell competition in intratumoral and tumor microenvironment interactions.The EMBO journal,2021,40(17):e107271.
54. Gao S, Hsu T, Li M. Immunity beyond cancer cells: perspective from tumor tissue.Trends in cancer,2021,7(11):1010-1019.
55. Havel J, Chowell D, Chan T. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.Nature reviews Cancer,2019,19(3):133-150.
56. Hennequin A, Derangère V, Boidot R, et al. Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients. Oncoimmunology, 2016, 5(2):e1054598.
57. Tortajada A, Gutierrez E, Pickering M, et al. The role of complement in IgA nephropathy.Molecular immunology,2019,114:123-132.
58. Tezuka H, Abe Y, Iwata M, et al. Regulation of IgA production by naturally occurring TNF/iNOS-producing dendritic cells.Nature,2007,448(7156):929-933.
59. Ma K, Li X, Lv J, et al. Correlations between CD4 FoxP3 Treg and expression of FoxM1 and Ki-67 in gastric cancer patients[J].Asia-Pacific journal of clinical oncology,2021,17(2):e63-e69.
60. Pernot S, Terme M, Radosevic-Robin N, et al. Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance[J]. Gastric Cancer,2020,23:73-81.